WO2001030826A1 - Nouveau polypeptide, une serine/threonine kinase 29, et polynucleotide codant pour ce polypeptide - Google Patents

Nouveau polypeptide, une serine/threonine kinase 29, et polynucleotide codant pour ce polypeptide Download PDF

Info

Publication number
WO2001030826A1
WO2001030826A1 PCT/CN2000/000392 CN0000392W WO0130826A1 WO 2001030826 A1 WO2001030826 A1 WO 2001030826A1 CN 0000392 W CN0000392 W CN 0000392W WO 0130826 A1 WO0130826 A1 WO 0130826A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
polynucleotide
serine
threonine kinase
seq
Prior art date
Application number
PCT/CN2000/000392
Other languages
English (en)
Chinese (zh)
Inventor
Yumin Mao
Yi Xie
Original Assignee
Shanghai Bio Road Gene Development Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Bio Road Gene Development Ltd. filed Critical Shanghai Bio Road Gene Development Ltd.
Priority to AU11268/01A priority Critical patent/AU1126801A/en
Publication of WO2001030826A1 publication Critical patent/WO2001030826A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention belongs to the field of biotechnology. Specifically, the present invention describes a novel polypeptide, serine / threonine kinase 29, and a polynucleotide sequence encoding the polypeptide. The invention also relates to a preparation method and application of the polynucleotide and the polypeptide.
  • Protein phosphorylation is a basic regulatory mechanism in the regulation of eukaryotic cells, and it is also the most common way of protein modification. For example, cell phosphorylation occurs during cell division, cell metabolism, cell adhesion and cell migration, cell-to-cell communication, and signaling. To accomplish these functions, 2% to 4% of human-encoded genes encode approximately 2000 different kinases (Hunter, 1996).
  • serine / threonine kinases are a large family.
  • a mouse testis-specific serine / threonine kinase (tssk) l (Bielke et al., 1994) has been isolated in 1994. This kinase is a new subfamily of serine / threonine kinases.
  • tssk serine / threonine kinase 2
  • tssk serine / threonine kinase 2
  • Immunohistochemical staining indicates that both kinases are located in the cytoplasm of late spermatids, and they have a significant effect on the last stage of sperm cell maturation. Sequence analysis showed that the ts sk2 gene had an open reading frame of 357 amino acids encoded by 1,071 nucleotides.
  • the protein's kinase domain is located at the amino terminus of the peptide chain (12-275 amino acids) and contains all conserved amino acids of the serine / threonine kinase family (Hanks and Puinn, 1991).
  • the tssk2 kinase domain has 89% homology with the human gene DGS-G (Gong et al., 1996), and tsskl has 84% homology.
  • ts skl, tssk2 and DGS-G form a new serine / threonine kinase subfamily-tssk family.
  • the functional domains of these three kinases are very similar, except that tssk2, the carboxyl terminus of the DGS-G peptide chain is conserved, and ts skl peptide chains have different amino acid sequences and lengths.
  • the entire nucleotide sequence of the tssk2 gene is very similar to that of the DGS-G gene, and DGS-G is also limited to expression in the human testis.
  • the tssk2 gene may be an orthologous gene of the DGS-G gene (Gong et al., 1996). DGS-G gene-specific transcription of 11 critical 250-kb DiGeorge critical regions In one recording unit, the gene is located on the 22nd human chromosome.
  • the polypeptide of the present invention is derived from a human cDNA library, has a high homology with the serine / threonine kinase subfamily-t s sk family, and has similar structural characteristics. It is named Serine / Threonine Kinase 29.
  • Another object of the invention is to provide a polynucleotide encoding the polypeptide.
  • Another object of the present invention is to provide a genetically engineered host cell comprising a polynucleotide encoding a serine / threonine kinase 29.
  • Another object of the present invention is to provide a method for producing serine / threonine kinase 29.
  • Another object of the present invention is to provide an antibody against the polypeptide of the present invention, serine / threonine kinase 29.
  • Another object of the present invention is to provide mimic compounds, antagonists, agonists, and inhibitors against the polypeptide of the present invention-serine / threonine kinase 29.
  • a novel isolated serine / threonine kinase 29 is provided.
  • the polypeptide is of human origin and comprises: a polypeptide having the amino acid sequence of SEQ ID NO: 2; or a conservative variant polypeptide thereof; Or its active fragment, or its active derivative, analog.
  • the polypeptide is a polypeptide having the amino acid sequence of SEQ ID NO: 2.
  • a polynucleotide encoding these isolated polypeptides, the polynucleotide comprising a nucleotide sequence having at least 70 nucleotides with a nucleotide sequence selected from the group consisting of % Identity: (a) a polynucleotide encoding the above-mentioned serine / threonine kinase 29; (b) a polynucleotide complementary to the polynucleotide (a).
  • the polynucleotide encodes a polypeptide having the amino acid sequence shown in SEQ ID NO: 2.
  • the sequence of the polynucleotide is one selected from the group consisting of: (a) a sequence having positions 1069-1650 in SEQ ID NO: 1; and (b) a sequence having 1-2345 in SEQ ID NO: 1 Sequence of bits.
  • a vector containing the above polynucleotide, and a host cell transformed or transduced by the vector or a host cell directly transformed or transduced by the above polynucleotide are provided.
  • Fig. 1 is a comparison diagram of amino acid sequence homology between serine / threonine kinase 29 and murine protein kinase of the present invention.
  • the upper sequence is serine / threonine kinase 29 and the lower sequence is murine protein kinase.
  • Identical amino acids are represented by single-character amino acids between the two sequences, and similar amino acids are represented by "+”.
  • Figure 2 shows the polyacrylamide gel electrophoresis (SDS-PAGE) of the isolated serine / threonine kinase 29.
  • 21 kDa is the molecular weight of the protein.
  • the arrow indicates the isolated protein band.
  • isolated refers to the separation of a substance from its original environment (if it is a natural substance, the original environment is the natural environment).
  • polynucleotides and polypeptides in a natural state in a living cell are not isolated and purified, but the same polynucleotides or polypeptides are separated and purified if they are separated from other substances in the natural state .
  • isolated serine / threonine kinase 29 means that serine / threonine kinase 29 is substantially free of other proteins, lipids, carbohydrates, or other substances with which it is naturally associated.
  • Those skilled in the art can purify serine / threonine kinase 29 using standard protein purification techniques. Substantially pure polypeptides produce a single main band on a non-reducing polyacrylamide gel. The purity of the serine / threonine kinase 29 peptide can be analyzed by amino acid sequence.
  • the present invention provides a novel polypeptide-serine / threonine kinase 29, which is basically composed of the amino acid sequence shown in SEQ ID NO: 2.
  • the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide, or a synthetic polypeptide, and preferably a recombinant polypeptide.
  • the polypeptides of the invention can be naturally purified products, or chemically synthesized products, or produced using recombinant techniques from prokaryotic or eukaryotic hosts (e.g., bacteria, yeast, higher plants, insects, and mammalian cells). Depending on the host used in the recombinant production protocol, the polypeptide of the invention may be glycosylated, or it may be non-glycosylated. Polypeptides of the invention may also include or exclude starting methionine residues.
  • the invention also includes fragments, derivatives and analogs of serine / threonine kinase 29.
  • fragment refers to a polypeptide that substantially maintains the same biological function or activity of the serine / threonine kinase 29 of the invention.
  • a fragment, derivative or analog of the polypeptide of the present invention may be: (I) a kind in which one or more amino acid residues are substituted with conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the substitution
  • the amino acid may or may not be encoded by a genetic codon; or ( ⁇ ) a type in which a group on one or more amino acid residues is replaced by another group to include a substituent; or ( ⁇ ⁇ )
  • Such a polypeptide sequence in which the mature polypeptide is fused with another compound such as a compound that prolongs the half-life of the polypeptide, such as polyethylene glycol
  • a polypeptide sequence in which an additional amino acid sequence is fused into the mature polypeptide (Such as a leader sequence or a secreted sequence or a sequence used to purify this polypeptide or a protease sequence)
  • such fragments, derivatives, and analogs are considered to be within the knowledge of those skilled in the art.
  • the present invention provides an isolated nucleic acid (polynucleotide), which basically consists of a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2.
  • the polynucleotide sequence of the present invention includes the nucleotide sequence of SEQ ID NO: 1.
  • the polynucleotide of the present invention is found from a cDNA library of human fetal brain tissue. It contains a polynucleotide sequence with a total length of 2345 bases, and its open reading frame (1069-1650) encodes 193 amino acids.
  • this peptide is 48% homologous to murine protein kinase, and it can be deduced that the serine / threonine kinase 29 has similar structure and function to murine protein kinase.
  • the polynucleotide of the present invention may be in the D form or the R form.
  • the D form includes cD, genomic DNA, or synthetic DNA.
  • DNA can be single-stranded or double-stranded.
  • DNA can be coding or non-coding.
  • the coding region sequence encoding the mature polypeptide may be the same as the coding region sequence shown in SEQ ID NO: 1 or a degenerate variant.
  • a "degenerate variant" refers to a nucleic acid sequence encoding a protein or polypeptide having SEQ ID NO: 2 but having a sequence different from the coding region sequence shown in SEQ ID NO: 1 in the present invention.
  • the polynucleotide encoding the mature polypeptide of SEQ ID NO: 2 includes: only the coding sequence of the mature polypeptide; the coding sequence of the mature polypeptide and various additional coding sequences; the coding sequence of the mature polypeptide (and optional additional coding sequences); Coding sequence.
  • polynucleotide encoding a polypeptide refers to a polynucleotide comprising the polypeptide and a polynucleotide comprising additional coding and / or non-coding sequences.
  • the present invention also relates to a variant of the polynucleotide described above, which encodes the same amino group as the present invention.
  • Variants of this polynucleotide may be naturally occurring allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants, and insertion variants.
  • an allelic variant is an alternative form of a polynucleotide that may be a substitution, deletion, or insertion of one or more nucleotides, but does not substantially change the function of the polypeptide it encodes .
  • the present invention also relates to a polynucleotide that hybridizes to the sequence described above (having at least 50%, preferably 70% identity, between the two sequences).
  • the present invention particularly relates to polynucleotides that can hybridize to the polynucleotides of the present invention under stringent conditions.
  • "strict conditions” means: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2xSSC, 0.1% SDS, 60'C; or (2) A denaturant was added during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% F i co ll, 42.
  • hybridizable polynucleotide has the same biological function and activity as the mature polypeptide shown in SEQ ID NO: 2.
  • nucleic acid fragments that hybridize to the sequences described above.
  • a "nucleic acid fragment” contains at least 10 nucleotides in length, preferably at least 20-30 nucleotides, more preferably at least 50-60 nucleotides, most preferably at least 100 More than nucleotides.
  • Nucleic acid fragments can also be used in nucleic acid amplification techniques (such as PCR) to identify and / or isolate polynucleotides encoding serine / threonine kinase 29.
  • polypeptides and polynucleotides in the present invention are preferably provided in an isolated form and are more preferably purified to homogeneity.
  • the specific polynucleotide sequence encoding the serine / threonine kinase 29 of the present invention can be obtained by various methods.
  • polynucleotides are isolated using hybridization techniques well known in the art. These techniques include, but are not limited to: 1) hybridization of probes to genomic or cDNA libraries to detect homologous polynucleotide sequences, and 2) antibody screening of expression libraries to detect cloned polynucleosides with common structural characteristics Acid fragments.
  • the D fragment sequence of the present invention can also be obtained by the following methods: 1) isolating the double-stranded DNA sequence from the genomic DNA; 2) chemically synthesizing the DNA sequence to obtain the double-stranded DNA of the polypeptide.
  • genome D is the least commonly used. Direct chemical synthesis of DNA sequences is often the method of choice.
  • the more commonly used method is the isolation of cDNA sequences.
  • the standard method for isolating cDNA of interest is to isolate mRNA from donor cells that overexpress the gene and perform reverse transcription to form a plasmid or phage cDNA library.
  • Q i agene There are many mature techniques for mRNA extraction, and kits are also commercially available (Q i agene).
  • the construction of cDNA libraries is also a common method (Sambrook, et al., Molecular Cloning, A Laboratory Manua 1, Cold Harbor Harbor Laboratory. New York, 1989).
  • Commercially available cDNA libraries are also available, such as different cDNA libraries from Clontech. When polymerase reaction technology is used in combination, even very few Expression products can also be cloned.
  • genes of the present invention can be selected from these cDNA libraries by conventional methods. These methods include (but are not limited to): (l) DM-DNA or DM-RNA hybridization; (2) the presence or absence of marker gene functions; (3) determination of the level of serine / threonine kinase 29 transcripts; ( 4) Detecting gene-expressed protein products by immunological techniques or by measuring biological activity. The above methods can be used singly or in combination.
  • the probe used for hybridization is homologous to any part of the polynucleotide of the present invention, and its length is at least 10 nucleotides, preferably at least 30 nucleotides, more preferably At least 50 nucleotides, preferably at least 100 nucleotides.
  • the length of the probe is usually within 2000 nucleotides, preferably within 1000 nucleotides.
  • the probe used here is generally a DNA sequence chemically synthesized based on the gene sequence information of the present invention.
  • the genes or fragments of the present invention can of course be used as probes.
  • DNA probes can be labeled with radioisotopes, luciferin, or enzymes (such as alkaline phosphatase).
  • immunological techniques such as Western blotting, radioimmunoprecipitation, and enzyme-linked immunosorbent assay (ELISA) can be used to detect protein products expressed by the serine / threonine kinase 29 gene.
  • ELISA enzyme-linked immunosorbent assay
  • a method (Sa iki, et al. Science 1985; 230: 1350-1354) using PCR technology to amplify DNA / RNA is preferably used to obtain the gene of the present invention.
  • the RACE method RACE-Rapid Amplification of cDNA Ends
  • the primers used for PCR can be appropriately based on the polynucleotide sequence information of the present invention disclosed herein. Select and synthesize using conventional methods.
  • the amplified DNA / RNA fragments can be isolated and purified by conventional methods such as by gel electrophoresis.
  • polynucleotide sequence of the gene of the present invention or various D fragments and the like obtained as described above can be determined by a conventional method such as a dideoxy chain termination method (Sanger et al. PNAS, 1977, 74: 5463-5467). Such polynucleotide sequences can also be determined using commercial sequencing kits and the like. To obtain the full-length cD sequence, the sequencing must be repeated. Sometimes it is necessary to determine the cDNA sequence of multiple clones in order to splice into a full-length cDNA sequence.
  • the present invention also relates to a vector comprising a polynucleotide of the present invention, and a host cell produced by genetic engineering using the vector of the present invention or directly using a serine / threonine kinase 29 coding sequence, and the recombinant technology to produce the polypeptide of the present invention Methods.
  • a polynucleotide sequence encoding a serine / threonine kinase 29 may be inserted into a vector, In order to constitute a recombinant vector containing the polynucleotide of the present invention.
  • vector refers to bacterial plasmids, phages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses, or other vectors well known in the art.
  • Vectors suitable for use in the present invention include, but are not limited to: T7 promoter-based expression vectors (Rosenberg, et al.
  • any plasmid and vector can be used to construct a recombinant expression vector.
  • An important feature of expression vectors is that they usually contain an origin of replication, a promoter, a marker gene, and translational regulatory elements.
  • Methods well known to those skilled in the art can be used to construct expression vectors containing a DNA sequence encoding a serine / threonine kinase 29 and appropriate transcriptional / translational regulatory elements. These methods include in vitro recombinant DNA technology, DNA synthesis technology, and in vivo recombination technology (Sambroook, et al. Molecular Cloning, A Laboratory Manua, Cold Spring Harbor Laboratory. New York, 1989).
  • the DNA sequence can be operably linked to an appropriate promoter in an expression vector to guide mRNA synthesis. Representative examples of these promoters are: the lac or trp promoter of E.
  • the expression vector also includes a ribosome binding site and a transcription terminator for translation initiation. Insertion of enhancer sequences into the vector will enhance its transcription in higher eukaryotic cells. Enhancers are cis-acting factors for DNA expression, usually about 10 to 300 base pairs, which act on promoters to enhance gene transcription. Illustrative examples include SV40 enhancers of 100 to 270 base pairs on the late side of the origin of replication, polyoma enhancers on the late side of the origin of replication, and adenovirus enhancers.
  • the expression vector preferably contains one or more selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance, and green for eukaryotic cell culture.
  • selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance, and green for eukaryotic cell culture.
  • GFP fluorescent protein
  • tetracycline or ampicillin resistance for E. coli.
  • a polynucleotide encoding a serine / threonine kinase 29 or a recombinant vector containing the polynucleotide can be transformed or transduced into a host cell to constitute a genetic engineered gene containing the polynucleotide or the recombinant vector.
  • Programmed host cells refers to a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples are: E.
  • coli Streptomyces
  • bacterial cells such as Salmonella typhimurium
  • fungal cells such as yeast
  • plant cells such as fly S2 or Sf 9
  • animal cells such as CH0, COS or Bowes melanoma cells.
  • Transformation of a host cell with a DNA sequence according to the present invention or a recombinant vector containing the D sequence can be performed using conventional techniques well known to those skilled in the art.
  • the host is a prokaryote such as E. coli
  • competent cells capable of absorbing D may be in the exponential growth phase were harvested, treated with CaC l 2 method used in steps well known in the art. The alternative is to use MgC l 2 .
  • transformation can also be performed by electroporation.
  • the following DNA transfection methods can be used: calcium phosphate co-precipitation method, or conventional mechanical methods such as microinjection, electroporation, and liposome packaging.
  • the polynucleotide sequence of the present invention can be used to express or produce recombinant serine / threonine kinase 29 by conventional recombinant DNA technology (Science, 1984; 224: 1431). Generally there are the following steps:
  • the medium used in the culture may be selected from various conventional mediums according to the host cells used. Culture is performed under conditions suitable for host cell growth. After the host cells have grown to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
  • a suitable method such as temperature conversion or chemical induction
  • the recombinant polypeptide may be coated in a cell, expressed on a cell membrane, or secreted outside the cell.
  • recombinant proteins can be separated and purified by various separation methods using their physical, chemical and other properties. These methods are well known to those skilled in the art. These methods include, but are not limited to: conventional renaturation treatment, protein precipitant treatment (salting out method), centrifugation, osmotic disruption, ultrasonic treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion Exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods.
  • polypeptide of the present invention and the antagonists, agonists and inhibitors of the polypeptide can be directly used in the treatment of diseases, for example, it can treat malignant tumors, adrenal deficiency, skin diseases, various types of inflammation, H IV infection and immunity Sexually transmitted diseases.
  • the serine / threonine kinase 29 of the present invention can also be expressed in the myocardium of early embryonic tissues. This indicates that the polypeptide of the present invention may be involved in cardiac development. At the same time, the serine / threonine kinase 29 of the present invention may also have a cascading effect on tumorigenesis. Deletion of the serine / threonine kinase 29 gene of the present invention will likely lead to Digeorge syndrome and facial deformity syndrome. These syndromes are manifested as developmental disorders such as hypodevelopment of the thymus and parathyroid glands, cardiovascular disorders, and mild craniofacial deformities.
  • the invention also provides methods for screening compounds to identify agents that increase (agonist) or suppress (antagonist) serine / threonine kinase 29.
  • Agonists enhance biological functions such as serine / threonine kinase 29 to stimulate cell proliferation, while antagonists prevent and treat disorders related to excessive cell proliferation, such as various cancers.
  • mammalian cells or membrane preparations expressing serine / threonine kinase 29 can be cultured with labeled serine / threonine kinase 29 in the presence of drugs. The ability of the drug to increase or block this interaction is then determined.
  • Antagonists of serine / threonine kinase 29 include screened antibodies, compounds, receptor deletions, and the like. Antagonists of serine / threonine kinase 29 can bind to serine / threonine kinase 29 and eliminate its function, or inhibit the production of the polypeptide, or bind to the active site of the polypeptide so that the polypeptide cannot exert its biology Features.
  • serine / threonine kinase 29 can be added to bioanalytical assays to determine whether a compound is Antagonist. Receptor deletions and analogs that act as antagonists can be screened in the same way as for screening compounds described above.
  • Polypeptide molecules capable of binding to serine / threonine kinase 29 can be obtained by screening a random peptide library composed of various possible combinations of amino acids bound to a solid phase. When screening, the serine / threonine kinase 29 molecule should generally be labeled.
  • the present invention provides a method for producing antibodies using polypeptides, and fragments, derivatives, analogs or cells thereof as antigens. These antibodies can be polyclonal or monoclonal antibodies.
  • the invention also provides antibodies directed against a serine / threonine kinase 29 epitope. These antibodies include (but are not limited to): polyclonal antibodies, monoclonal antibodies, chimeric antibodies, single chain antibodies, Fab fragments, and fragments generated from Fab expression libraries.
  • Polyclonal antibodies can be produced by direct injection of serine / threonine kinase 29 into immunized animals (such as rabbits, mice, rats, etc.).
  • immunized animals such as rabbits, mice, rats, etc.
  • a variety of adjuvants can be used to enhance the immune response, including but not limited to 'S adjuvant and so on.
  • Techniques for preparing monoclonal antibodies to serine / threonine kinase 29 include, but are not limited to, hybridoma technology (Kohler and Miste in. Nature, 1975, 256: 495-497) t -tumor technology human B-cell hybridoma Technology * EBV-hybridoma technology, etc.
  • Chimeric antibodies that bind human constant regions and non-human-derived variable regions can be produced using existing techniques (Morrison et al, PNAS, 1985, 81: 6851).
  • the existing technology for producing single chain antibodies (US Pat No. 4946778) can also be used to produce single chain antibodies against serine / threonine kinase 29.
  • Antibodies against serine / threonine kinase 29 can be used in immunohistochemical techniques to detect serine / threonine kinase 29 in biopsy specimens.
  • Monoclonal antibodies that bind to serine / threonine kinase 29 can also be labeled with radioisotopes and injected into the body to track their location and distribution.
  • This radiolabeled antibody can be used as a non-invasive diagnostic method to locate tumor cells and determine whether there is metastasis.
  • Antibodies can also be used to design immunotoxins that target a particular part of the body.
  • serine / threonine kinase 29 high affinity monoclonal antibodies can covalently bind to bacterial or plant toxins (such as diphtheria toxin, ricin, ormosine, etc.).
  • a common method is to attack the amino group of an antibody with a thiol cross-linking agent such as SPDP and bind the toxin to the antibody through the exchange of disulfide bonds.
  • This hybrid antibody can be used to kill serine / threonine kinase 29 positive cell.
  • the antibodies of the present invention can be used to treat or prevent diseases related to serine / threonine kinase 29.
  • Administration of an appropriate dose of the antibody can stimulate or block the production or activity of serine / threonine kinase 29.
  • the invention also relates to a diagnostic test method for quantitative and localized detection of serine / threonine kinase 29 levels.
  • tests are well known in the art and include FISH assays and radioimmunoassays.
  • Serine / threonine kinase 29 levels measured in the test can be used to explain the importance of serine / threonine kinase 29 in various diseases and to diagnose diseases in which serine / threonine kinase 29 plays a role.
  • polypeptide of the present invention can also be used for peptide mapping analysis.
  • the polypeptide can be specifically cleaved by physical, chemical or enzymatic analysis, and subjected to one-dimensional or two-dimensional or three-dimensional gel electrophoresis analysis, and more preferably mass spectrometry analysis.
  • Polynucleotides encoding serine / threonine kinase 29 can also be used for a variety of therapeutic purposes. Gene therapy techniques can be used to treat abnormalities in cell proliferation, development, or metabolism caused by non-expression or abnormal / inactive expression of serine / threonine kinase 29. Recombinant gene therapy vectors (such as viral vectors) can be designed to express variant serine / threonine kinase 29 to inhibit endogenous serine / threonine kinase 29 activity.
  • a variant serine / threonine kinase 29 can be shortened and lack signaling
  • Expression vectors derived from viruses ⁇ Retroviruses, adenoviruses, adenovirus-associated viruses, herpes simplex virus, parvoviruses, and the like can be used to transfer a polynucleotide encoding a serine / threonine kinase 29 into a cell.
  • a method for constructing a recombinant viral vector carrying a polynucleotide encoding a serine / threonine kinase 29 can be found in the existing literature (Sambrook, et al.).
  • a recombinant polynucleotide encoding serine / threonine kinase 29 can be packaged into liposomes and transferred into cells.
  • Methods for introducing a polynucleotide into a tissue or cell include: directly injecting the polynucleotide into a tissue in vivo; or introducing the polynucleotide into a cell in vitro through a vector (such as a virus, phage, or plasmid), and then transplanting the cell Into the body and so on.
  • a vector such as a virus, phage, or plasmid
  • Oligonucleotides including antisense RNA and DM
  • ribozymes that inhibit serine / threonine kinase 29 mRNA are also within the scope of the present invention.
  • a ribozyme is an enzyme-like RNA molecule that can specifically decompose a specific R. Its mechanism of action is that the ribozyme molecule specifically hybridizes to a complementary target RNA for endonucleation.
  • Antisense RNA, DNA, and ribozymes can be obtained using any existing RNA or DNA synthesis technology, such as solid-phase phosphoramidite chemical synthesis to synthesize oligonucleotides.
  • Antisense RNA molecules can be obtained by in vitro or in vivo transcription of a DNA sequence encoding the RNA. This DNA sequence has been integrated downstream of the RNA polymerase promoter of the vector. In order to increase the stability of the nucleic acid molecule, it can be modified in a variety of ways, such as increasing the sequence length on both sides, and the linkage between ribonucleosides using phosphorothioate or peptide bonds instead of phosphodiester bonds.
  • a polynucleotide encoding a serine / threonine kinase 29 can be used for the diagnosis of diseases related to serine / threonine kinase 29.
  • a polynucleotide encoding a serine / threonine kinase 29 can be used to detect the expression of serine / threonine kinase 29 or the abnormal expression of serine / threonine kinase 29 in a disease state.
  • a DNA sequence encoding serine / threonine kinase 29 can be used to hybridize biopsy specimens to determine the expression of serine / threonine kinase 29.
  • Hybridization techniques include Southern blotting, Nor thern imprinting, and in situ hybridization. These techniques and methods are all mature and open technologies, and related kits are commercially available. Part or all of the polynucleotides of the present invention can be immobilized on a microarray as probes
  • Serine / threonine kinase 29-specific primers can also be used for RNA-polymerase chain reaction (RT-PCR) in vitro amplification to detect serine / threonine kinase 29 transcription products. Detection of mutations in the serine / threonine kinase 29 gene can also be used to diagnose serine / threonine kinase 29-related diseases.
  • the forms of serine / threonine kinase 29 mutations include point mutations, translocations, deletions, recombinations, and any other abnormalities compared to normal wild-type serine / threonine kinase 29 DNA sequences. Mutations can be detected using existing techniques such as Southern blotting, DNA sequence analysis, PCR and in situ hybridization. In addition, mutations may affect protein expression. Therefore, Northern blotting and Western blotting can be used to indirectly determine whether a gene is mutated.
  • the sequences of the invention are also valuable for chromosome identification.
  • the sequence specifically targets a specific position on a human chromosome and can hybridize to it.
  • specific sites for each gene on the chromosome need to be identified.
  • only a few chromosome markers based on actual sequence data are available for marking chromosome positions.
  • an important first step is to locate these DNA sequences on a chromosome.
  • PCR primers (preferably 15-35bp) are prepared based on cD, and the sequences can be located on chromosomes. These primers were then used for PCR screening of somatic hybrid cells containing individual human chromosomes. Only those heterozygous cells containing the human gene corresponding to the primer will produce amplified fragments.
  • PCR localization of somatic hybrid cells is a quick way to locate D to a specific chromosome.
  • oligonucleotide primers of the present invention in a similar manner, a set of fragments from a specific chromosome or a large number of genomic clones can be used to achieve sublocalization.
  • Other similar strategies that can be used for chromosomal localization include in situ hybridization, chromosome pre-screening with labeled flow sorting, and pre-selection of hybridization to construct chromosome-specific cDNA libraries.
  • Fluorescent in situ hybridization of cDNA clones with metaphase chromosomes allows precise chromosomal localization in one step.
  • FISH Fluorescent in situ hybridization
  • the physical location of the sequence on the chromosome can be correlated with the genetic map data. This data can be found in, for example, V. Mckusick, Mendelian Inherance in Man (available online with Johns Hopkins University Welch Medical Library). Linkage analysis can then be used to determine the relationship between genes and diseases that have been mapped to chromosomal regions.
  • the differences in cDNA or genomic sequences between the affected and unaffected individuals need to be determined. If a mutation is observed in some or all diseased individuals, and the mutation is not observed in any normal individual, The mutation may be the cause of the disease. Comparing affected and unaffected individuals usually involves first looking for structural changes in the chromosome, such as deletions or translocations that are visible at the chromosomal level or detectable using cDNA sequence-based PCR. According to the resolution capabilities of current physical mapping and gene mapping technology, the cDNA accurately mapped to the chromosomal region associated with the disease can be one of 50 to 500 potentially pathogenic genes (assuming 1 megabase mapping resolution) Capacity and each 20kb corresponds to a gene).
  • the polypeptides, polynucleotides and mimetics, agonists, antagonists and inhibitors of the present invention can be used in combination with a suitable pharmaceutical carrier.
  • suitable pharmaceutical carrier can be water, glucose, ethanol, salts, buffers, glycerol, and combinations thereof.
  • the composition comprises a safe and effective amount of the polypeptide or antagonist, and carriers and excipients which do not affect the effect of the drug. These compositions can be used as drugs for the treatment of diseases.
  • the invention also provides a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the invention.
  • a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the invention.
  • these containers there may be instructional instructions given by government agencies that manufacture, use, or sell pharmaceuticals or biological products, which prompts permission for administration on the human body by government agencies that produce, use, or sell.
  • the polypeptides of the invention can be used in combination with other therapeutic compounds.
  • the pharmaceutical composition can be administered in a convenient manner, such as by a topical, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal route of administration.
  • Serine / threonine kinase 29 is administered in an amount effective to treat and / or prevent a specific indication.
  • the amount and range of serine / threonine kinase 29 administered to a patient will depend on many factors, such as the mode of administration, the health conditions of the person to be treated, and the judgment of the diagnostician. Examples
  • the determined CDM sequence was compared with an existing public DM sequence database (Genebank), and it was found that the CDM sequence of one of the clones 0097dl 0 was new DNA.
  • a series of primers were synthesized to determine the inserted cDNA fragments of the clone in both directions.
  • the results show that the 0097dl 0 clone contains a full-length cDNA of 2345bp (as shown in Seq ID N0: l), and has a 193bp open reading frame (0RF) from 1069bp to 1650bp, encoding a new protein (such as Seq ID NO: 2).
  • This clone pBS-0097dlO and the encoded protein was named serine / threonine kinase 29.
  • Example 2 Homologous search of cDNA clones
  • the sequence of the serine / threonine kinase 29 of the present invention and the protein sequence encoded by the serine / threonine kinase 29 of the present invention were analyzed using the Blas t program (Basic local alignment search tool) [Altschul, SF et al. J. Mol. Biol. 1990; 215: 403- 10]. Perform homology search in databases such as Genbank and Swissport.
  • the gene most homologous to the serine / threonine kinase 29 of the present invention is a known murine protein kinase, and the accession number of the encoded protein is Gen019 in Genbank. The two are highly homologous, with an identity of 48% and a similarity of 69%.
  • Example 3 Cloning of a gene encoding serine / threonine kinase 29 by RT-PCR
  • CDNA was synthesized using fetal brain total RNA as a template and ol igo-dT as a primer for reverse transcription reaction. After purification with Qiagene's kit, the following primers were used for PCR amplification:
  • Pr imer 1 5'-GAGAAAAGGAGCAGGCCAAGGGC-3 '(SEQ ID NO: 3)
  • Primer2 5'-CTTTTACCCAATTTCCTTTAATGG-3 '(SEQ ID NO: 4)
  • Primerl is a forward sequence starting at lbp of the 5th end of SEQ ID NO: 1;
  • Primer2 is the 3, terminal reverse sequence of SEQ ID NO: 1.
  • RNA extraction in one step [Anal. Biochem 1987, 162, 156-159] rempliThis method involves acid guanidinium thiocyanate phenol-chloroform extraction. 4M guanidinium isothiocyanate-25 mM sodium citrate, 0.2 ⁇ 1 Sodium acetate ( ⁇ .0) was used to homogenize the tissue, 1 volume of phenol and 1/5 volume of chloroform-isoamyl alcohol (49: 1) were added, and the mixture was centrifuged. The aqueous layer was aspirated, and isopropyl alcohol ( 0.8 volume) and the mixture was centrifuged to obtain an RNA pellet. The resulting RNA pellet was washed with 70% ethanol, dried and dissolved in water.
  • RNA 20 ⁇ 8 RNA was used in 20 mM 3- (N-morpholino) propanesulfonic acid (PH7 .0) was electrophoresed on a 1.2% agarose gel -5m -ImM EDTA-2.2M sodium acetate, formaldehyde and then transferred to nitrocellulose.
  • the DNA probe used was the PCR-amplified serine / threonine kinase 29 coding region sequence (1069bp to 1650bp) shown in Figure 1.
  • a 32P-labeled probe (about 2 x 10 6 cpm / ml) hybridized with RNA-transferred nitrocellulose membrane at 42 ° C overnight in a solution containing 50% formamide-25mM KH 2 P0 4 (pH7.4) -5 33 (-5 ⁇ 0 61111 & 1 ⁇ , 3 solution and 20,048 / 1111 salmon sperm 0 hybridization Thereafter, the filters in 1 x SSC- 0.1% SDS are washed at 55 ° C 30min. Then, analyzed and quantified by Phosphor Imager.
  • Example 5 Recombinant Expression, isolation and purification of serine / threonine kinase 29 in vitro
  • Priraer3 5,-CCCCATATGATGCTAGAGTCTGCCGACGGGAAA-3 '(Seq ID No: 5)
  • Primer4 5'-CCCGAATTCTCAAGTGCTTGCTAGCCATGGATG-3' (Seq ID No: 6)
  • the 5 'ends of these two primers contain Ndel and EcoRI restriction sites, respectively.
  • the coding sequences of the 5 'and 3' ends of the gene of interest are followed, respectively.
  • the Ndel and EcoRI restriction sites correspond to the selectivity within the expression vector plasmid pET-28b (+) (Novagen, Cat. No. 69865.3) Digestion site.
  • the pBS-0097dl0 plasmid containing the full-length target gene was used as a template for the PCR reaction.
  • the PCR reaction conditions were as follows: 10 pg of pBS-0097dl0 plasmid, primer Primer-3, and Primer_4 were included in a total volume of 50 ⁇ l; j was lpmol, Advantage polymerase Mix (Clontech) 1 ⁇ 1. Cycle parameters: 94 ° C 20s, 60 ° C 30s, 68. C 2 min, a total of 25 cycles. Ndel and EcoRI were used to double digest the amplified product and plasmid pET-28 (+), respectively, and large fragments were recovered and ligated with T4 ligase.
  • the ligation product was transformed by the calcium chloride method of coliform bacteria DH5 alpha, containing kanamycin After the LB plate (final concentration 30 g / ml) was cultured overnight, positive clones were selected by colony PCR method and sequenced. A positive clone (pET-0097dlO) with the correct sequence was selected, and the recombinant plasmid was transformed into E. coli BL21 (DE3) plySs (product of Novagen) by the calcium chloride method.
  • host strain BL21 P ET-0097dlO
  • IPTG IPTG
  • the following peptides specific to serine / threonine kinase 29 were synthesized using a peptide synthesizer (product of PE): NH 2 -Me t -Leu-G lu-Ser-Ala-As ⁇ -G 1 y-Ly s-11 e-Cys-Leu-Va 1 -Me t -G 1 u-Leu-COOH (SEQ ID NO: 7).
  • the polypeptide is coupled to hemocyanin and bovine serum albumin to form a complex, respectively. For methods, see: Avrameas, et al. Immunochemistry, 1969; 6: 43.
  • Rabbits were immunized with 4 mg of the hemocyanin polypeptide complex plus complete Freund's adjuvant, and 15 days later, the hemocyanin polypeptide complex plus incomplete Freund's adjuvant was used to boost immunity once. 15 using a 15 ⁇ g / ml bovine serum albumin peptide complex-coated titer plate for ELISA to determine the antibody titer in rabbit serum. Total IgG was isolated from antibody-positive rabbit serum using protein A-Sepharose. The peptide was bound to a cyanogen bromide-activated Sepharose4B column, and anti-peptide antibodies were separated from the total IgG by affinity chromatography. Immunoprecipitation demonstrated that the purified antibodies specifically bind to serine / threonine kinase 29.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un nouveau polypeptide, une sérine/thréonine kinase 29, et un polynucléotide codant pour ce polypeptide ainsi qu'un procédé d'obtention de ce polypeptide par des techniques recombinantes d'ADN. L'invention concerne en outre les applications de ce polypeptide dans le traitement de maladies, notamment des tumeurs malignes, de l'hémopathie, de l'infection par VIH, de maladies immunitaires et de diverses inflammations. L'invention concerne aussi l'antagoniste agissant contre le polypeptide et son action thérapeutique ainsi que les applications de ce polynucléotide codant pour la sérine/thréonine kinase 29.
PCT/CN2000/000392 1999-10-27 2000-10-27 Nouveau polypeptide, une serine/threonine kinase 29, et polynucleotide codant pour ce polypeptide WO2001030826A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU11268/01A AU1126801A (en) 1999-10-27 2000-10-27 A novel polypeptide-serine/threonine kinase 29 and polynucleotide encoding said polypeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN99119860.3 1999-10-27
CN 99119860 CN1303945A (zh) 1999-10-27 1999-10-27 一种新的多肽——丝氨酸/苏氨酸激酶29和编码这种多肽的多核苷酸

Publications (1)

Publication Number Publication Date
WO2001030826A1 true WO2001030826A1 (fr) 2001-05-03

Family

ID=5281151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2000/000392 WO2001030826A1 (fr) 1999-10-27 2000-10-27 Nouveau polypeptide, une serine/threonine kinase 29, et polynucleotide codant pour ce polypeptide

Country Status (3)

Country Link
CN (1) CN1303945A (fr)
AU (1) AU1126801A (fr)
WO (1) WO2001030826A1 (fr)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIELKE W. ET AL.: "Characterization of a novel murine testis-specific serine/threonine kinases", GENE, vol. 139, no. 2, 1994, pages 235 - 239 *
KUENG P. ET AL.: "A novel family of serine/threonine kinases participating in spermiogenesis", J. CELL BIOL., vol. 139, no. 7, 1997, pages 1851 - 1859 *

Also Published As

Publication number Publication date
AU1126801A (en) 2001-05-08
CN1303945A (zh) 2001-07-18

Similar Documents

Publication Publication Date Title
WO2001038522A1 (fr) Nouveau polypeptide, histone humaine h2a.21, et polynucleotide codant pour ce polypeptide
WO2001031030A1 (fr) Nouveau polypeptide, phosphodiesterase 21 humaine de type acide sphingomyelinase, et polynucleotide codant pour ce polypeptide
WO2001029228A1 (fr) Nouveau polypeptide, caseine kinase humaine 48, et polynucleotide codant pour ce polypeptide
WO2001030826A1 (fr) Nouveau polypeptide, une serine/threonine kinase 29, et polynucleotide codant pour ce polypeptide
WO2001030818A1 (fr) Nouveau polypeptide, proteine de liaison 33 a l'arn, et polynucleotide codant pour ce polypeptide
WO2001031024A1 (fr) Nouveau polypeptide, threonine synthetase 71, et polynucleotide codant pour ce polypeptide
WO2001030837A1 (fr) Nouveau polypeptide, galectine 15, et polynucleotide codant pour ce polypeptide
WO2001038540A1 (fr) Nouveau polypeptide, la methionyl arnt synthetase humaine de 29 kda, et polynucleotide codant pour ledit polypeptide
WO2001038545A1 (fr) Nouveau polypeptide, acetyle galactosyle transferase 45 humain et polynucleotide codant ce polypeptide
WO2001030840A1 (fr) Nouveau polypeptide, une proteine 57 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001030832A1 (fr) Nouveau polypeptide, proteine a doigt de zinc hkznf-23, et un polynucleotide codant pour ce polypeptide
WO2001030833A1 (fr) Nouveau polypeptide, proteine de regulation d'un nouveau cycle cellulaire 53, et polynucleotide codant pour ce polypeptide
WO2001030819A1 (fr) Nouveau polypeptide, tropomoduline humaine 39, et polynucleotide codant pour ce polypeptide
WO2001029075A1 (fr) Nouveau polypeptide, proteine 129 activant la proteine g, et polynucleotide codant pour ce polypeptide
WO2001038370A1 (fr) Nouvelle sous-unite 49 de l'activateur de transcription polypeptidique et polynucleotide codant ce polypeptide
WO2001027285A1 (fr) Nouveau polypeptide, methyltransferase humaine dpb 41 et polynucleotide codant pour ce polypeptide
WO2001027283A1 (fr) Nouveau polypeptide, proteine 16 de type transcriptase humaine inverse, et polynucleotide codant pour ce polypeptide
WO2001029229A1 (fr) Nouveau polypeptide, proteine humaine 20 de liaison de retinoblastome et polynucleotide le codant
WO2001030821A1 (fr) Nouveau polypeptide, arn cyclase humaine 41, et polynucleotide codant pour ce polypeptide
WO2001030823A1 (fr) Nouveau polypeptide, proteine humaine canal circulaire 69, et polynucleotide codant pour ce polypeptide
WO2001031022A1 (fr) Nouveau polypeptide, arginyl arnt synthetase 44, et polynucleotide codant pour ce polypeptide
WO2001032863A1 (fr) Nouveau polypeptide, proteine humaine 12 associee a l'apoptose (sag), et polynucleotide codant pour ce polypeptide
WO2001030835A1 (fr) Nouveau polypeptide, pogo transposase humaine 14, et polynucleotide codant pour ce polypeptide
WO2002026975A1 (fr) Nouveau polypeptide, proteine humaine 48-35.53 associee au rhomboide, et polynucleotide codant ce polypeptide
WO2001030822A1 (fr) Nouveau polypeptide, pyrophosphatase humaine 26 dutp, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP